Prognostic significance of CYFRA 21-1 in non-small cell lung cancer

Tomonori Hirashima; Minoru Takada; Takefumi Komiya; Takashi Nitta; Kobayashi Masashi; Noriyuki Masuda; Kaoru Matui; Masanori Kikui; Tsutomu Yasumitsu; Ichirou Kawase

Prognostic significance of CYFRA 21-1 in non-small cell lung cancer

Tomonori Hirashima, Minoru Takada, Takefumi Komiya, Takashi Nitta, Kobayashi Masashi, Noriyuki Masuda, Kaoru Matui, Masanori Kikui, Tsutomu Yasumitsu, Ichirou Kawase

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymun-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P < 0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P = 0.0040 for CYFRA 21-1, P < 0.001 for PS, P = 0.0052 for Stage).

Original language	English (US)
Pages (from-to)	4713-4716
Number of pages	4
Journal	Anticancer Research
Volume	18
Issue number	6 B
State	Published - 1998

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{99a7b542d2ba4cbf907504fdbe990dcf,

title = "Prognostic significance of CYFRA 21-1 in non-small cell lung cancer",

abstract = "Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymun-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P < 0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P = 0.0040 for CYFRA 21-1, P < 0.001 for PS, P = 0.0052 for Stage).",

author = "Tomonori Hirashima and Minoru Takada and Takefumi Komiya and Takashi Nitta and Kobayashi Masashi and Noriyuki Masuda and Kaoru Matui and Masanori Kikui and Tsutomu Yasumitsu and Ichirou Kawase",

year = "1998",

language = "English (US)",

volume = "18",

pages = "4713--4716",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6 B",

}

TY - JOUR

T1 - Prognostic significance of CYFRA 21-1 in non-small cell lung cancer

AU - Hirashima, Tomonori

AU - Takada, Minoru

AU - Komiya, Takefumi

AU - Nitta, Takashi

AU - Masashi, Kobayashi

AU - Masuda, Noriyuki

AU - Matui, Kaoru

AU - Kikui, Masanori

AU - Yasumitsu, Tsutomu

AU - Kawase, Ichirou

PY - 1998

Y1 - 1998

N2 - Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymun-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P < 0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P = 0.0040 for CYFRA 21-1, P < 0.001 for PS, P = 0.0052 for Stage).

AB - Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymun-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P < 0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P = 0.0040 for CYFRA 21-1, P < 0.001 for PS, P = 0.0052 for Stage).

UR - http://www.scopus.com/inward/record.url?scp=0032423812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032423812&partnerID=8YFLogxK

M3 - Article

C2 - 9891546

AN - SCOPUS:0032423812

SN - 0250-7005

VL - 18

SP - 4713

EP - 4716

JO - Anticancer Research

JF - Anticancer Research

IS - 6 B

ER -

Prognostic significance of CYFRA 21-1 in non-small cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this